• Yun-Ling Wong, Samantha Sampson, Willem Andreas Germishuizen, Sunali Goonesekera, Giovanni Caponetti, Jerry Sadoff, Barry R Bloom, and David Edwards.
• Division of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
• Proc. Natl. Acad. Sci. U.S.A. 2007 Feb 20; 104 (8): 2591-5.

AbstractWith the increasing incidence of tuberculosis and drug resistant disease in developing countries due to HIV/AIDS, there is a need for vaccines that are more effective than the present bacillus Calmette-Guérin (BCG) vaccine. We demonstrate that BCG vaccine can be dried without traditional freezing and maintained with remarkable refrigerated and room-temperature stability for months through spray drying. Studies with a model Mycobacterium (Mycobacterium smegmatis) revealed that by removing salts and cryoprotectant (e.g., glycerol) from bacterial suspensions, the significant osmotic pressures that are normally produced on bacterial membranes through droplet drying can be reduced sufficiently to minimize loss of viability on drying by up to 2 orders of magnitude. By placing the bacteria in a matrix of leucine, high-yield, free-flowing, "vial-fillable" powders of bacteria (including M. smegmatis and M. bovis BCG) can be produced. These powders show relatively minor losses of activity after maintenance at 4 degrees C and 25 degrees C up to and beyond 4 months. Comparisons with lyophilized material prepared both with the same formulation and with a commercial formulation reveal that the spray-dried BCG has better overall viability on drying.

14 keywords...

hide…